Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis

European Respiratory Journal

Volumn 46, Issue 2, 2015, Pages 444-455

  Van Der Paardt, Anne Fleur ^a   Wilffert, Bob ^a,b   Akkerman, Onno W ^a   De Lange, Wiel C M ^a   Van Soolingen, Dick ^c,d   Sinha, Bhanu ^a   Van Der Werf, Tjip S ^a   Kosterink, Jos G W ^a,b   Alffenaar, Jan Willem C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; KETOLIDE; MACROLIDE; RIBOSOME RNA; ROXITHROMYCIN; TELITHROMYCIN; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; DEINOCOCCUS RADIODURANS; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HUMAN; IMMUNOMODULATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; WORLD HEALTH ORGANIZATION; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84938854855     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00147014     Document Type: Article

References (96)

1. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO progress report 2011. Geneva, World Health Organization, 2011.
2. Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-629.
3. Dooley KE, Obuku EA, Durakovic N, et al. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis 2013; 207: 1352-1358.
4. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. Geneva, World Health Organization, 2011.
5. World Health Organization. Global tuberculosis report 2012. Geneva, World Health Organization, 2012.
6. World Health Organization. Global tuberculosis report 2014. Geneva, World Health Organization, 2014.
7. Zumla A, Abubakar I, Raviglione M, et al. Drug-resistant tuberculosis - current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis 2012; 205: Suppl. 2, S228-S240.
8. Cohen T, Jenkins HE, Lu C, et al. On the spread and control of MDR-TB epidemics: an examination of trends in anti-tuberculosis drug resistance surveillance data. Drug Resist Updat 2014; 17: 105-123.
9. Perdigo J, Macedo R, Silva C, et al. From multidrug-resistant to extensively drug-resistant tuberculosis in Lisbon, Portugal: the stepwise mode of resistance acquisition. J Antimicrob Chemother 2013; 68: 27-33.
10. Jalava J, Marttila H. Application of molecular genetic methods in macrolide, lincosamide and streptogramin resistance diagnostics and in detection of drug-resistant Mycobacterium tuberculosis. APMIS 2004; 112: 838-855.
11. Retsema J, Fu W. Macrolides: structures and microbial targets. Int J Antimicrob Agents 2001; 18: Suppl. 1, S3-10.
12. Buriánková K, Doucet-Populaire F, Dorson O, et al. Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex. Antimicrob Agents Chemother 2004; 48: 143-150.
13. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
14. Ji B, Jamet P, Perani EG, et al. Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrob Agents Chemother 1996; 40: 2137-2141.
15. Chan GP, Garcia-Ignacio BY, Chavez VE, et al. Clinical trial of clarithromycin for lepromatous leprosy. Antimicrob Agents Chemother 1994; 38: 515-517.
16. Grosset JH. Newer drugs in leprosy. Int J Lepr Other Mycobact Dis 2001; 69: S14-S18.
17. Nienhuis WA, Stienstra Y, Thompson WA, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010; 375: 664-672.
18. Alffenaar JW, Nienhuis WA, de Velde F, et al. Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. Antimicrob Agents Chemother 2010; 54: 3878-3883.
19. Griffith DE, Wallace RJ Jr. New developments in the treatment of nontuberculous mycobacterial (NTM) disease. Semin Respir Infect 1996; 11: 301-310.
20. Fernandes PB, Hardy DJ, McDaniel D, et al. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 1989; 33: 1531-1534.
21. Schlünzen F, Harms JM, Franceschi F, et al. Structural basis for the antibiotic activity of ketolides and azalides. Structure 2003; 11: 329-338.
22. Schlünzen F, Zarivach R, Harms J, et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 2001; 413: 814-821.
23. Pfister P, Jenni S, Poehlsgaard J, et al. The structural basis of macrolide-ribosome binding assessed using mutagenesis of 23S rRNA positions 2058 and 2059. J Mol Biol 2004; 342: 1569-1581.
24. Champney WS, Burdine R. Macrolide antibiotics inhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 2141-2144.
25. Chittum HS, Champney WS. Erythromycin inhibits the assembly of the large ribosomal subunit in growing Escherichia coli cells. Curr Microbiol 1995; 30: 273-279.
26. Rastogi N, Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob Agents Chemother 1991; 35: 462-470.
27. Altenburg J, de Graaff CS, van der Werf TS, et al. Immunomodulatory effects of macrolide antibiotics - part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration 2011; 81: 75-87.
28. Zarogoulidis P, Papanas N, Kioumis I, et al. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012; 68: 479-503.
29. Parnham MJ. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005; 18: 125-131.
30. Sharma S, Jaffe A, Dixon G. Immunomodulatory effects of macrolide antibiotics in respiratory disease: therapeutic implications for asthma and cystic fibrosis. Paediatr Drugs 2007; 9: 107-118.
31. Healy DP. Macrolide immunomodulation of chronic respiratory diseases. Curr Infect Dis Rep 2007; 9: 7-13.
32. Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010; 138: 1202-1212.
33. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000; 292: 156-163.
34. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013; 309: 1251-1259.
35. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Dieases (ESCMID). EUCAST Definitive Document E.Def 1.2, May 2000: terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin Microbiol Infect 2000; 6: 503-508.
36. Cavalieri SJ, Biehle JR, Sanders WE Jr. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 1542-1545.
37. Stoffels K, Traore H, Vanderbist F, et al. The effect of combined tobramycin-clarithromycin on Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis 2009; 13: 1041-1044.
38. Bergmann JS, Woods GL. In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 1998; 2: 621-626.
39. Luna-Herrera J, Reddy VM, Daneluzzi D, et al. Antituberculosis activity of clarithromycin. Antimicrob Agents Chemother 1995; 39: 2692-2695.
40. Bosne-David S, Barros V, Verde SC, et al. Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors. J Antimicrob Chemother 2000; 46: 391-395.
41. Hoffner SE, Gezelius L, Olsson-Liljequist B. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1997; 40: 885-888.
42. Yew WW, Piddock LJ, Li MS, et al. In-vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother 1994; 34: 343-351.
43. Lu PL, Peng CF, Hwang JJ, et al. Activity of twelve second-line antimicrobial agents against Mycobacterium tuberculosis in Taiwan. J Chemother 2008; 20: 202-207.
44. Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 1996; 33: 167-175.
45. Rastogi N, Goh KS, Ruiz P, et al. In vitro activity of roxithromycin against the Mycobacterium tuberculosis complex. Antimicrob Agents Chemother 1995; 39: 1162-1165.
46. Umubyeyi A, Rigouts L, Shamputa IC, et al. Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Rwanda. Int J Infect Dis 2008; 12: 152-156.
47. Falzari K, Zhu Z, Pan D, et al. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005; 49: 1447-1454.
48. Sato K, Tomioka H, Akaki T, et al. Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. Int J Antimicrob Agents 2000; 16: 25-29.
49. Tomioka H, Sato K, Sano C, et al. Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells. Antimicrob Agents Chemother 2002; 46: 519-521.
50. Abate G, Miörner H, Ahmed O, et al. Drug resistance in Mycobacterium tuberculosis strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs. Int J Tuberc Lung Dis 1998; 2: 580-584.
51. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109.
52. Escudero E, Pea JM, Alvarez-Sala R, et al. Multidrug-resistant tuberculosis without HIV infection: success with individualised therapy. Int J Tuberc Lung Dis 2006; 10: 409-414.
53. Ferrara G, Richeldi L, Bugiani M, et al. Management of multidrug-resistant tuberculosis in Italy. Int J Tuberc Lung Dis 2005; 9: 507-513.
54. Drobniewski F, Eltringham I, Graham C, et al. A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK. Thorax 2002; 57: 810-816.
55. Morcillo N, Di Giulio B, Testani B, et al. A microplate indicator-based method for determining the susceptibility of multidrug-resistant Mycobacterium tuberculosis to antimicrobial agents. Int J Tuberc Lung Dis 2004; 8: 253-259.
56. Abubakar I, Moore J, Drobniewski F, et al. Extensively drug-resistant tuberculosis in the UK: 1995 to 2007. Thorax 2009; 64: 512-515.
57. Bolhuis MS, van der Laan T, Kosterink JG, et al. In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis. Eur Respir J 2014; 44: 808-811.
58. Ramn-Garca S, Ng C, Anderson H, et al. Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. Antimicrob Agents Chemother 2011; 55: 3861-3869.
59. Klemens SP, DeStefano MS, Cynamon MH. Therapy of multidrug-resistant tuberculosis: lessons from studies with mice. Antimicrob Agents Chemother 1993; 37: 2344-2347.
60. Truffot-Pernot C, Lounis N, Grosset JH, et al. Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 2827-2828.
61. Bolhuis MS, van Altena R, van Soolingen D, et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J 2013; 42: 1614-1621.
62. Seung KJ, Becerra MC, Atwood SS, et al. Salvage therapy for multidrug-resistant tuberculosis. Clin Microbiol Infect 2014; 20: 441-446.
63. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9: e1001300.
64. Shean KP, Willcox PA, Siwendu SN, et al. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis 2008; 12: 1182-1189.
65. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 2006; 12: 1389-1397.
66. Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45: 1290-1295.
67. Hutchison DC, Drobniewski FA, Milburn HJ. Management of multiple drug-resistant tuberculosis. Respir Med 2003; 97: 65-70.
68. Carroll MW, Lee M, Cai Y, et al. Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort. Int J Tuberc Lung Dis 2012; 16: 961-966.
69. Törün T, Güngör G, Ozmen I, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 1373-1377.
70. Williams B, Ramroop S, Shah P, et al. Multidrug-resistant tuberculosis in UK children: presentation, management and outcome. Eur Respir J 2013; 41: 1456-1458.
71. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-574.
72. Shean K, Streicher E, Pieterson E, et al. Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS One 2013; 8: e63057.
73. Mor N, Esfandiari A. Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. Antimicrob Agents Chemother 1997; 41: 2035-2036.
74. Patel KB, Xuan D, Tessier PR, et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996; 40: 2375-2379.
75. Conte JE Jr, Golden JA, Duncan S, et al. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob Agents Chemother 1995; 39: 334-338.
76. Rodvold KA, Gotfried MH, Danziger LH, et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997; 41: 1399-1402.
77. Mor N, Vanderkolk J, Heifets L. Accumulation of clarithromycin in macrophages infected with Mycobacterium avium. Pharmacotherapy 1994; 14: 100-104.
78. Ishiguro M, Koga H, Kohno S, et al. Penetration of macrolides into human polymorphonuclear leucocytes. J Antimicrob Chemother 1989; 24: 719-729.
79. Jia L, Tomaszewski JE, Hanrahan C, et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 2005; 144: 80-87.
80. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
81. Fortn J, Martn-Dávila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005; 56: 180-185.
82. Alffenaar JW, van der Laan T, Simons S, et al. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob Agents Chemother 2011; 55: 1287-1289.
83. Balasubramanian V, Solapure S, Iyer H, et al. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob Agents Chemother 2014; 58: 495-502.
84. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405: 962-966.
85. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006; 3: e466.
86. Kannan K, Vázquez-Laslop N, Mankin AS. Selective protein synthesis by ribosomes with a drug-obstructed exit tunnel. Cell 2012; 151: 508-520.
87. Krokidis MG, Márquez V, Wilson DN, et al. Insights into the mode of action of novel fluoroketolides, potent inhibitors of bacterial protein synthesis. Antimicrob Agents Chemother 2014; 58: 472-480.
88. Champney WS, Tober CL. Structure-activity relationships for six ketolide antibiotics. Curr Microbiol 2001; 42: 203-210.
89. U.S. Food and Drug Administration. Telithromycin (marketed as Ketek) Information. www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm107824.htm Date last accessed: September 14, 2014. Date last updated: January 19, 2010.
90. Clay KD, Hanson JS, Pope SD, et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006; 144: 415-420.
91. Brown SD. Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia. Drug Saf 2008; 31: 561-575.
92. Volberg WA, Koci BJ, Su W, et al. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther 2002; 302: 320-327.
93. Simk J, Csilek A, Karászi J, et al. Proarrhythmic potential of antimicrobial agents. Infection 2008; 36: 194-206.
94. Pranger AD, van Altena R, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011; 38: 888-894.
95. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
96. Worley MV, Estrada SJ. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis. Pharmacotherapy 2014; 34: 1187-1197.